Tripos to Build One of the Leading Informatics-Driven Drug Discovery Laboratories in Europe
- State-of-the-Art Chemical Synthesis Facilities to be Built in Cornwall, England -
Advertisement
ST. LOUIS, MO - April 25, 2002 - Responding to worldwide demand by pharmaceutical and biotechnology companies to accelerate timelines in the discovery of new drugs and therapeutics for the marketplace, the leading provider of drug discovery chemistry, software and enterprise informatics, Tripos, Inc., today announced it will significantly expand its Tripos Receptor Research facility and intends to considerably increase its workforce, in Bude, Cornwall, England. The new facility will more than double Tripos' current chemistry laboratories to 65,000 sq. ft., expand its personnel to 230 people, and is expected to be fully operational in early 2004.
This significant expansion will provide Tripos with the scientific staff and infrastructure to meet the growing demand for its informatics-driven discovery research products and services, including the recently announced four-year, $100 million agreement with pharmaceutical giant Pfizer to design, synthesize and purify high-quality, drug-like compounds to expand their high-throughput screening compound collection.
Tripos Receptor Research is a premiere scientific research facility that uses proprietary information-driven technologies to enhance the efficient design and synthesis of chemical compound libraries. These highly-focused LeadQuest® libraries are used around the world by leading drug discovery companies such as Pfizer, Lipha S.A. (the French subsidiary of Merck KgA), and others to identify promising new drug candidates. Tripos' drug discovery services include refinement (or optimization) processes for the compounds that demonstrate desired biological activity against the defined drug target. Known for problem solving, Tripos technologies rescue stalled discovery projects and navigate around patented chemical space to quickly move discovery projects forward for its customers.
Most read news
Topics
Organizations
Other news from the department business & finance
These products might interest you
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
CIM® Monolithic Well Plates | Multiwell plates | Sartorius
Max-Planck-Institut für experimentelle Medizin - Göttingen, Germany
Max-Planck-Institut für Kolloid- und Grenzflächenforschung - Potsdam, Germany
Truffini & Reggè Farmaceutici S.r.l. - Mailand, Italy
Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK Gatersleben) - Gatersleben, Germany
From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines
Simtra BioPharma Solutions - Parsippany, USA
Ancient viral DNA shapes modern human placentas - “It’s a reminder that there is much more to learn about our genome and how ancient infections can influence who we are today”
Chemistry meets biology: controlling artificial cell membranes through catalysis - Researchers develop an artificial metalloenzyme-based platform that enables programmable control of artificial membrane behavior
Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology - Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market